Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847489 | 0.83 | HDAC3 (0.39) | ALDH1A1TSHRMEN1KMT2ATP53 | |
| SCHEMBL4062839 | 0.80 | PRMT5 (0.36) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL4057475 | 0.78 | TBXAS1 (0.55) | KDM4EALDH1A1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL24035608 | 0.78 | MEN1 (0.52) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL10194702 | 0.78 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL10196841 | 0.77 | GAA (0.40) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL4054492 | 0.77 | HTT (0.62) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL11402474 | 0.76 | MEN1 (0.52) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL4050698 | 0.76 | MEN1 (0.46) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR | |
| Bromide SCHEMBL5751833 | 0.76 | HTT (0.61) | KDM4EALDH1A1SMN1; SMN2HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511038-B2 | Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-31 | — | — | US | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| CN-1878759-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-12-13 | — | — | CN | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | KDM4E 571/4885ALDH1A1 193/4885SMN1; SMN2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.